NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.